

Afisi S Ismaila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3772966/publications.pdf>

Version: 2024-02-01

25
papers

500
citations

932766

10
h-index

752256

20
g-index

25
all docs

25
docs citations

25
times ranked

544
citing authors

#	ARTICLE	IF	CITATIONS
1	<p><p>Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review</p>. International Journal of COPD, 2020, Volume 15, 439-460.	0.9	173
2	<p><p>Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review</p>. International Journal of COPD, 2020, Volume 15, 417-438.	0.9	43
3	Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review. BMC Research Notes, 2015, 8, 464.	0.6	36
4	INTREPID: single- <i>versus</i> multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Research, 2021, 7, 00950-2020.	1.1	35
5	Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. Medical Decision Making, 2017, 37, 469-480.	1.2	29
6	Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. Medical Decision Making, 2017, 37, 453-468.	1.2	24
7	<p><p>Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial</p>. International Journal of COPD, 2019, Volume 14, 2681-2695.	0.9	24
8	Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Research, 2018, 4, 00047-2018.	1.1	22
9	<p><p>Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease</p>. International Journal of COPD, 2019, Volume 14, 2121-2129.	0.9	14
10	COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners. International Journal of COPD, 2018, Volume 14, 51-63.	0.9	13
11	<p><p>Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective</p>. International Journal of COPD, 2020, Volume 15, 1621-1632.	0.9	13
12	Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEK/VI) Following a COPD Exacerbation. International Journal of COPD, 2022, Volume 17, 491-504.	0.9	11
13	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEK/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Advances in Therapy, 2022, 39, 3957-3978.	1.3	10
14	Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice. International Journal of COPD, 2021, Volume 16, 1255-1264.	0.9	9
15	Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. International Journal of COPD, 2021, Volume 16, 2591-2604.	0.9	9
16	<p>Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and Germany</p>. International Journal of COPD, 2020, Volume 15, 595-604.	0.9	8
17	Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. Respiratory Medicine, 2018, 145, 130-137.	1.3	5
18	<p><p>Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study</p>. International Journal of COPD, 2019, Volume 14, 939-951.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. ERJ Open Research, 2022, 8, 00333-2021.	1.1	5
20	Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation, 2018, 16, 17.	0.6	4
21	Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England. International Journal of COPD, 2022, Volume 17, 415-426.	0.9	3
22	Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England. International Journal of COPD, 2021, Volume 16, 2795-2808.	0.9	2
23	Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of COPD, 2021, Volume 16, 3105-3118.	0.9	2
24	Treatment Preferences of Patients with Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups in the United Kingdom, United States, and Germany. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 19-30.	0.5	1
25	Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. International Journal of COPD, 0, Volume 17, 1455-1466.	0.9	0